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SummaηWe  compared prostatic specific acid phosphatase CP AP)， prostatic spe-
cific antigen CP A) and γ-seminoprotein Cγ-SM) 1eve1s between bone marrow and serum 
for the purpose of assessing of the usefu1ness of these tumor markers in ear1y detection of 
bone metastasis in cases with prostatic cancer. Thirty-three patients were entered into this 
study. Of the patients， 20 had prostatic cancer inc1uding 11 with bone metastasis， and 13 
patients had benign prostatic hypertrophy CBPH) served as contro1s. It seemed unlike1y 
that bone marrow PAP， PA and γSM are more usefu1 than their serum 1eve1s for detection 
of bone metastasis of prostatic cancer. Because corre1ation between bone marrow and 
serum 1eve1s of each marker was observed not on1y in cases with prostate cancer ac-
companied by bone metastasis but a1so in metastasis-free prostatic cancer and BPH cases， 
it seems like1y that PAP， PA and γ-SM in bone marrow circu1ate. from periphera1 b100d 
rather than from bone metastasis of prostatic cancer. 
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INTRODUCTION 
Prostatic specific acid phosphatase CPAP)， prostatic secific antigen CPA) and γ-semino】
protein Cγ-SM) in bone marrow are used as markers of prostatic cancer as well as in serum. 
However， itis controversia1 whether or not these markers in bone marrow are usefu1 in the 
ear1y detection of bone metastasis of prostatic cancer. We recent1y ana1yzed prostatic tumor 
markers in bone marrow with severa1 noteworthy findings. 
MATERIALS AND METHODS 
Thirty-three patients were entered into the study from 1986 to 1988 after informed consent 
was obtained at Nara Medica1 University or affi1iated hospita1s. The patients ranged in age 
from 53 to 86 years， with a mean age of 70.3 years. They inc1uded 20 cases with prostatic cancer 
which were histo1ogically diagnosed. The remaining 13 cases were c1inically suspected pros-
tatic cancer ; however， they were diagnosed as benign prostatic hypertrophyCBPH)histopatho目
10gically and served as contro1s in this study. All 20 cases of prostatic cancer examined were 
untreated fresh cases or re1apsed cases. All cases with prostatic cancer underwent pa1pation， 
pe1vic computerized tomography， transrecta1 prostatic u1trasonography， vesicu1ography， 
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lymphography， plain bone roentgenography and bone scintigraphy. Based on the results of 
these examinations， 3 cases were determined as Stage B2， 5 cases as Stage C， 1 case Stage D1 
and 11 cases as Stage D2 according to the Rules for General Rule for C1inical and Pathological 
Studies on Prostatic Cancer estab1ished jointly by the J apanese Urological Association and the 
J apanese Pathological Society in 1985. All of the Stage D2 cases had bone metastases (Table 
1). 
Bone marrow fluid， about 10ml， was sampled via the anterior iliac crest using a Komiya's 
needle. PAP was determined with a PAP RIA Kit (Eiken Chemimal Co.， Ltd.， Tokyo). PA 
and y-SM were detemined by enzyme immunoassay using a Markit FPA (Dainippon Pharma-
ceutical Co.， Ltd.， Osaka) and a γSM Kit Chugai (Chugai Pharmaceutical Co.， Ltd.， Tokyo)， 
respectively. 
At the same time， cytological examination was performed using Papanicolaou method. In 
addition， PAP， PA and γ-SM in serum， collected on the same day as bone marrow sampling， 
were determined. 
RESULTS 
A shown in Table 2， serum and bone marrow levels of PAP， PA andγ-SM were compared 
among the following three groups of paitents: (1) patients with BPH(BPH group)， (2)patients 
with stage D2 prostatic cancer accompanied by bone metastasis (metastasis group)， and (3) 
patients with stage B， C or D1 prostate cancer without bone metastasis (metastasis-free 
group). 
Significant differences in serum and bone marrow P AP were observed between the 
metastasis and BPH groups， and between the metastasis and metastasis-free groups. Serum 
and bone marrow P A significantly differed between the BPH and metastasis groups. In 
analysis of the significance of inter-group difference ofγ-SM， the only significant difference 
was that of serum γ-SM observed between the BPH and metastasis groups.羽Thenserum levels 
Table 1. Patient characteristics 
Tota! No町Pts. 33 
Age 53-86 y同 o. (Mean 70.3) 
Patho!ogy B.P.H. 13 
Prostatic cencer 
20 








Mod: Mod巴rate!ydiferentiated adenocarcinorna 
Por: Poorly diferentiated adenocarcinorna 
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Table 2. Serum and bone marrow PAP， PA and γSM levels 
BPH Prostatic cancer 
With Metastasis Without Metastasis 
Total No. pts 13 1 9 
PAP 
serum 2.3士l.6") 14.8土12目1")b) 5.3:t8.1b) 
bone marrow 4.3土5.0C) 20.2士24.2C)d) 5. O:t5. 6d) 
PA 
serum 3.3土2.6e) 36. 7:t38. ge) 13.6士18.1
bone marrow 2.6土2.3') 3l.2土32.3') 11.1土15.2
γ-SM 
serum 3.6土2.5") 10. 5:t6. 5g) 7.4士7.1
bone marrow 6.6土12.9 12.0士9.3 9.8士9.8
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Fig. 1. Correlation between bone marrow and serum levels of PAP 
Y=0.923X+3.03， R=0.770 (pく0.01)with bone meta 
R=0.953 (p<O.01) without bone meta 
R=0.794 (p<O.01) BPH 
of PAP， PA and γ-SM were compared with bone marrow levels of the same markers in each 
group， no group showed any significant difference between the serum and bone marrow level 
of any marker. 
When correlation between serum and bone marrow levels of P AP was explored， a signifi幽
cant positive correlation was found (p < 0.01 ; Fig圃1).Significant positive correlation was also 
found between serum and bone marrow levels of P A and γ-SM (p<O.Ol; Fig.2 and 3). 
In cytological examination of bone marrow， only one case of stage D2 prostatic cancer was 
judged too be abnormal. 
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DISCUSSION 
In 1970， Chua et al.1) first reported that acid phosphatase in bone marrow was useful in the 
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Fig. 2. Correlation between bone marrow and serum levels of P A. 
Y=0.776X十1.035，R=0.916 (p<O.Ol) with bone meta 
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Rニ 0.967(p<O.Ol) without bone meta 
R=0.789 (p<O.Ol) BPH 
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Fig. 3. Correlation between bone marrow and serum levels ofγSM. 
Y=1.039X十2.23，R=0.879 (p<O.Ol) with bone meta 
R=0.861 (p<O.Ol) without bone meta 
R=0.905 (p<O.Ol) BPH 
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the usefulness of bone marrow acid phosphatase or prostatic specific acid phosphatase have 
been published2，3). However， with the recent use of radioimmunoassay， which is more specific 
to prostatic cancer for determination of bone marrow PAP level， reports have increasingly 
indicated the uselessness of bonemarrow PAP dermination for early detection of bone 
metastasis of prostatic cancer4-6). Bone marrow P A has been reported by Morote et al.6) to be 
of no aid in ear1y detection of bone metastasis of prostatic cancer. Regarding determination 
of bone marrow γ-SM， no report has been published. 
In the present study， we compared P AP， P A and γSM levels between bone marrow and 
serum in the present study for the purpose of assessing the usefulness of these tumor markers 
in the early detection of bone metastasis. Bone marrow PAP significantly differed between 
metastasis and metastasis-free groups. Serum P AP also significantly differed between these 
two groups. On the other hand， no significant inter-group difference was observed for bone 
marrow PA orγ-SM. When differences between serum and bone marrow levels were 
examined for each of PAP， PA and γSM in each group， no significant difference was observed. 
These results indicate that the bone marrow level of PAP. PA orγSM is not more useful than 
the serum level of these markers for detection of bone metastasis of prostatic cancer. 
To study the origin of these markers in bone marrow， we compared bone marrow and 
serum of each marker. The bone marrow level of each marker significantly correlated with the 
serum level of the corresponding marker not only in the metastasis group but also in the 
metastasis-free and BPHgroups. It is particularly noteworthy that patients with BPH showing 
elevated bone marrow levels of these markers， false positive cases in the diagnosis of prostatic 
cancer， also indicated elevation of serum levels of the same markers. That is， bone marrow 
levels of these markers reflected serum levels of the same markers in these cases of BPH. 
These results suggest that PAP， PA and γSM in bone marrow circulate from peripheral blood 
rather than from bone metastases of prostatic cancer. 
CRead at the 38th Annual Meeting of the Central Section of the Japanese Urological Associa同
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